Polls

Poll: How Much Progress With Biosimilars Has the United States Made?

April 28th 2021

With 20 biosimilar launches in the United States since 2015, opinions vary as to the strength of utilization.

Poll: What Is the Best Way to Improve Biosimilar Access?

April 14th 2021

Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.

Poll: How Can Patients Be Persuaded to Accept Biosimilars?

March 31st 2021

Opinions differ on what patients are more likely to respond to.

Harvard Paper: CMS Coding, Other Factors at Fault for Tepid Biosimilar Savings

March 21st 2021

By Tony Hagen

Biosimilars are intended to save money for the health care system, but for many reasons, they are not succeeding in this mission, Harvard authors argue.

Poll: How Much Discretion Should Payers Have Over Biosimilar Coverage?

March 17th 2021

Coverage policies for biosimilars in the health care industry are the source of much angst.

Biosimilars Quiz: Which years have brought AbbVie the highest revenues for adalimumab?

March 3rd 2021

Poll: What Will Be the Strongest Trend in 2021?

February 17th 2021

Which of these selections do you think is the most powerful trend in medicine to emerge from the pandemic?

Poll: How Much Do You Know About Biosimilars in China?

February 3rd 2021

Test your knowledge of biosimilar approvals in China.

Poll: Which of the following is true about insulin products and the BPCIA?

January 20th 2021

Many patient advocates hope that expansion of the Biologics Price Competition and Innovation Act (BPCIA) will bring further competition to the insulin market—and lower prices.

Biosimilars Poll: Which Way Will the Supreme Court Rule on the ACA?

November 16th 2020

The court must decide whether Congress’ setting the shared responsibility payment to $0 means that the entire Affordable Care Act (ACA) statute is now unconstitutional.